SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp XCN price surge and outsized candle are driving attention, with traders buying dips and speculating about a technical squeeze. Others say there is no clear XCN-specific catalyst and point to Bitcoins rebound as a possible factor.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following segments: Agency, Residential Credit, Mortgage Servicing Rights (MSR), and Corporate and Other. The Agency segment invests in agency mortgage-backed securities. The Residential Credit segment is involved in non-agency residential mortgage assets within securitized products and whole loan markets. The MSR segment provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

Annalys earnings discussion has centered on a book-value shortfall despite an earnings beat, alongside a sharp share-price slide and fresh lows. Traders are split between treating the high dividend and perceived discount as a buying opportunity and warning that rate volatility and further book-value pressure could make the yield risky.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports of Irth Capital pursuing a take-private deal with backing from Papa Johns largest U.S. franchisee are driving attention, with traders speculating about whether the board will engage or accept while others doubt a deal will materialize. Frustration over weak sales, the suspended dividend, and the companys declining performance fuels criticism of management and the board.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs co-founders plan to leave and start a new mRNA venture, alongside a weak outlook, prompting concerns about leadership, declining COVID-related revenue and the companys ability to advance its oncology pipeline. Some traders view the cash reserves and late-stage cancer programs as a counterweight, leaving the discussion divided between pipeline optimism and doubts about execution.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Attention centers on Reddits upcoming Q3 earnings and whether ad growth, user metrics, and AI data-licensing prospects can support the stock. Traders are split between optimism about ad momentum and prior earnings beats, and concern over user/traffic trends, insider selling, and persistent volatile price action.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

CCXI is drawing attention as the SPAC vehicle for Agility Robotics, with traders focused on its planned merger and exposure to humanoid robots used in warehouses and factories. Enthusiasm over the robotics theme, commercial deployments and major backers competes with concerns about valuation, losses, execution and typical post-merger SPAC volatility.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

IGV is attracting attention as software stocks rebound and show relative strength against semiconductors, reviving debate over whether AI will bolster established software businesses rather than disrupt them. Some traders see renewed sector leadership after the SaaSpocalypse selloff, while others view the move as a temporary rotation or warn that resistance could bring a pullback.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is under pressure amid doubts about Auvelitys launch for Alzheimers agitation: prescription trends have not accelerated as some investors expected, prompting questions about uptake, depression-treatment growth, and commercial execution ahead of the Nov. 2 quarterly results. Some bulls argue that samples and long-term-care channels may leave reported prescriptions understating demand, while managements silence and broader biotech weakness have added to uncertainty and selling.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Anticipation around Aerodromes merger with Velodrome and planned multichain expansion is driving attention, with traders expecting broader liquidity and revenue opportunities from the unified protocol. Sentiment is largely bullish, though some worry about added token supply, rollout delays, and a possible sell-the-news reaction.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is drawing attention after a sharp pullback erased a prior sessions gains, with traders focused on whether buyers will defend technical support. Some see the dip as a setup for a rebound, while others expect further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million.
Electra Therapeutics (NASDAQ:ETRA) stock roseread more...

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next 

Equity

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

Electra Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>The Health Care Select Sector SPDR Fund (XLV) gained 1.8% last week, outperforming the broader market and biotech ETFs.</li><li>Sellas Life Sciences (SLS) will present three preclinical SLS009 pancreatic-cancer studies at an AACR conference.</li><li>The Senate will hold a hearing Thursday on Heidi Overton’s nomination to lead the FDA.</li></ul><p>Biotech investors enter a catalyst-heavy week featuring Novo Nordisk’s strategy and pipeline update, Sellas Life Sciences’ SLS009 presentations, a Senate hearing on FDA leadership and at least two clinical updates still guided for the third quarter.</p><h2 class="st-heading-2"><strong>Healthcare Led The Market Last Week</strong></h2><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 1.8%, outperforming the broader market, while the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a> rose 0.9% and the<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a> slipped 0.09%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> and<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> added 0.8% and 0.3%, respectively.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_ef5dec4d7b.png" alt="healthcare.png"></p><h2 class="st-heading-2"><strong>This Week’s Biotech Catalyst Calendar&nbsp;</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Sept. 21</td><td>NVO</td><td>Capital Markets Day in London</td></tr><tr><td>Sept. 21</td><td>ETRA</td><td>First full week of Nasdaq trading after its $350 million IPO</td></tr><tr><td>Sept. 24</td><td>FDA</td><td>Hearing on Heidi Overton’s nomination as FDA commissioner</td></tr><tr><td>Sept. 25-28</td><td>SLS</td><td>Three preclinical SLS009 posters at AACR’s pancreatic-cancer conference</td></tr><tr><td>By Sept. 30</td><td>SCYX</td><td>Potential Phase 1 results for intravenous SCY-247</td></tr><tr><td>By Sept. 30</td><td>QURE</td><td>Potential four-year Phase 1/2 update for AMT-130</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Novo And Sellas Lead Scientific Calendar</strong></h2><p>Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday as it works to expand beyond the semaglutide franchise behind Ozempic and Wegovy. The event comes amid competition with Eli Lilly (LLY), which sells Mounjaro and Zepbound.</p><p>Novo recently adopted the shorter “Novo” brand while retaining Novo Nordisk as its legal name. CEO Mike Doustdar also introduced an updated “Novo Way” centered on customer obsession, competitiveness, clarity, and care and integrity. The company expects to launch CagriSema, its investigational cagrilintide-semaglutide combination, in 2027.</p><p>Sellas Life Sciences (SLS) will present three preclinical SLS009 posters at AACR’s pancreatic-cancer conference, which begins Friday in San Diego and runs through Sept. 28. SLS009 blocks CDK9, a protein that helps certain cancer cells survive and multiply. The research will examine its activity in laboratory models of KRAS-mutant pancreatic cancer, including combinations with BET and PARP inhibitors.&nbsp;</p><h2 class="st-heading-2"><strong>FDA Leadership And Q3 Readouts In Focus&nbsp;</strong></h2><p>The Senate Health, Education, Labor and Pensions Committee will hold a hearing Thursday on Heidi Overton’s nomination to lead the FDA. The FDA commissioner oversees reviews of drugs, vaccines, biologics and medical devices, along with policies governing clinical trials, manufacturing and post-market safety.&nbsp;</p><p>Scynexis (SCYX) has guided to third-quarter Phase 1 results for intravenous SCY-247 but has not set a release date. The experimental antifungal is being developed for invasive candidiasis and the prevention of invasive fungal disease.</p><p>UniQure (QURE) has separately guided to a four-year update from its Phase 1/2 AMT-130 study by quarter-end. The Huntington’s disease gene therapy can reduce production of the mutant huntingtin protein. The firm submitted its AMT-130 biologics license application earlier this month using three-year clinical data compared with an external control. The filing is complete, leaving the four-year update as the remaining quarter-end event.</p><h2 class="st-heading-2"><strong>Biotech IPO Pipeline Updates</strong></h2><p>Electra Therapeutics (ETRA) enters its first full week of trading after raising $350 million by selling 14 million shares at $25 each. The stock closed its Friday debut 12% below the IPO price. Electra’s pipeline is led by Veligrotug, an antibody for immune-related diseases.</p><p>Retension Pharmaceuticals and TRex Bio also filed for U.S. IPOs on Friday. Retension plans to list under RTSN and is developing cardiovascular drug RTN-001. TRex plans to trade under TRXB and is developing autoimmune and inflammatory-disease treatment TRB-061. Eli Lilly plans to invest in TRex alongside the offering.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-undervalued-analyst-roadster-barely-bull-case/cZMRTeURB47">TSLA Stock Looks ‘Slightly Undervalued’ To This Analyst — But The Roadster Is Barely Part Of The Bull Case&nbsp;</a></p>

SLS stock has surged 614% over the past year. (Photo credit: Getty Images)

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next

Electra Therapeautics

iShares Biotechnology ETF

Lilly(Eli) & Co

Novo Nordisk A/S

uniQure NV

Scynexis Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

ETRA News